Trade Filings
Manager Aktien Einreichungen Superinvestoren
Signale Institutionelles Kaufen Institutionelles Verkaufen Insider-Aktivität 13D & 13G Watch Sektorrotation
Tools Aktien-Screener Manager-Screener Manager vergleichen Konsensbaskets Alle Research-Tools Daten-API
Lernen & KI Lernen Daten befragen KI-Agenten
Nachrichten ★ Gespeichert
Über Über uns Methodik Kontakt Haftungsausschluss
Reader
DATENPLÄNE

Historische Datendownloads – verfügbar mit Konten.

API-GATEWAY

Kostenloser, lesender JSON-Zugriff auf die gecachten Daten der Website.

Dunkelmodus

🧭 Geführte Ansicht
Neu an den Märkten – Kurse, Renditen, YTD, Marktkapitalisierung? Wir erklären jeden Begriff beim Browsen, in verständlicher Sprache. Dieselben Daten, mit integrierter Hilfe.

⚡ Expertenansicht
Sie kennen den Markt bereits. Nur die Daten – sauber, schnell und kompakt, ohne zusätzliche Erläuterungen. Dies ist die Standardansicht.

Oberflächensprache
Wertpapierdatensatz · archiviertes Quartal

LLY

Eli Lilly and Company · Healthcare · Drug Manufacturers - General

1,233.5 -1.1% Marktkapitalisierung $1.16T Kurs verzögert (FMP) · per Aug 25 22:08 UTC — von den nachstehenden Meldedaten getrennt

Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024
193Erfasste Halter
+4Δ Inhaber
671.92MGehaltene Aktien
$804.91BGemeldeter Wert
+6Neue Positionen
−1Ausstiege
Stable Überzeugungsscore 48/100 Wie diese Werte berechnet werden → Am Research Desk erklären →

Momentum-Eingaben (vergleichbare Manager): Halterbreite +2.1% · Aktienfluss -0.1% · neue Nettopositionen +2.6%Formel
Eigentümerfragmentierung — mehr Halter, kleinere Gesamtbeteiligung

Alle Eigentumszahlen: nur beobachtete 13F-Manager, Stammaktienpositionen, Berichtszeitraum Q2 2026

Beteiligung im Zeitverlauf
QuartalInhaberΔAktienGemeldeter WertNeuAusstiege
Q2 2026 193 +4 671.92M $804.91B +6 −1
Q1 2026 191 -3 666.59M $613.20B +1 −5
Q4 2025 193 +2 707.04M $758.81B +3
Q3 2025 27 -3 329.88M $251.63B +2 −6
Q2 2025 28 -1 307.45M $239.60B +2 −3
Q1 2025 26 0 140.32M $115.83B +1 −1
Q4 2024 26 +1 145.00M $111.91B +3 −2
Q3 2024 24 +2 109.89M $97.29B +2
Q2 2024 22 112.43M $101.75B
Inhaberanzahl
Wer es hält · Q2 2026
#ManagerAktienΔ AnteileWertDeren GewichtungGehalten
1 Lilly Endowment Inc 90.38M -1.6% $108.40B 100.0% ▼ Trim 3 SEC ↗
2 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
3 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
4 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
5 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
6 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
7 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
8 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
9 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
10 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
11 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
12 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
13 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
14 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
15 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
16 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
17 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
18 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
19 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
20 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
21 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
22 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
23 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
24 BlackRock (passiv) 67.54M +1.8% $81.01B 1.2% ▲ Add 5 SEC ↗
25 Vanguard Capital Management Llc 53.53M +0.3% $64.20B 1.4% ▲ Add 2 SEC ↗
26 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
27 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
28 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
29 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
30 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
31 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
32 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
33 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
34 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
35 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
36 Pnc Financial Services Group, Inc. 51.32M 0.0% $61.56B 30.5% ▼ Trim 3 SEC ↗
37 State Street Global Advisors (passiv) 36.22M +1.7% $43.44B 1.3% ▲ Add 7 SEC ↗
38 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
39 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
40 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
41 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
42 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
43 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
44 Fidelity (FMR) 28.46M +8.1% $34.14B 1.5% ▲ Add 5 SEC ↗
45 Capital Research Global Investors 20.87M -15.3% $25.04B 3.5% ▼ Trim 3 SEC ↗
46 Geode Capital Management (passiv) 20.31M +0.6% $24.28B 1.3% ▲ Add 9 SEC ↗
47 Geode Capital Management (passiv) 20.31M +0.6% $24.28B 1.3% ▲ Add 9 SEC ↗
48 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
49 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
50 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
51 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
52 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
53 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
54 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
55 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
56 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
57 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
58 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
59 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
60 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
61 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
62 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
63 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
64 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
65 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
66 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
67 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
68 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
69 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
70 Morgan Stanley 16.23M +5.1% $19.46B 1.0% ▲ Add 4 SEC ↗
71 Capital World Investors 15.90M +1.8% $19.08B 2.3% ▲ Add 9 SEC ↗
72 T. Rowe Price 13.91M -0.6% $16.69B 1.7% ▼ Trim 9 SEC ↗
73 T. Rowe Price 13.91M -0.6% $16.69B 1.7% ▼ Trim 9 SEC ↗
74 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
75 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
76 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
77 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
78 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
79 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
80 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
81 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
82 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
83 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
84 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
85 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
86 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
87 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
88 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
89 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
90 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
91 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
92 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
93 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
94 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
95 JPMorgan Chase 12.60M -8.0% $15.50B 0.9% ▼ Trim 4 SEC ↗
96 Norges Bank (passiv) 11.47M Neu $13.76B 1.4% New 1 SEC ↗
97 Bank Of America Corp /De/ 11.27M +1.3% $13.52B 0.9% ▲ Add 3 SEC ↗
98 Bank Of America Corp /De/ 11.27M +1.3% $13.52B 0.9% ▲ Add 3 SEC ↗
99 Bank Of America Corp /De/ 11.27M +1.3% $13.52B 0.9% ▲ Add 3 SEC ↗
100 Bank Of America Corp /De/ 11.27M +1.3% $13.52B 0.9% ▲ Add 3 SEC ↗

„Ihre Gewichtung" = Anteil der Position am gemeldeten 13F-Eigenkapitalwert des jeweiligen Managers — das Conviction-Maß. ✦ = kuratorisch ausgewählter Manager.

Neue Käufer

Norges Bank $13.76B 1.4%

Ausgestiegen

Walleye Trading LLC $4.34M war 0.1%

Marktweiter Kontext: über ALLE 13F-Melder (strukturierte SEC-Daten, Q1 2026): 4,323 Inhaber, 762.84M Anteile, $674.93B gemeldet. Dies ist ein anderer, älterer Zeitraum als die oben genannten Zahlen des erfassten Universums; beide werden niemals vermischt.

Häufig gemeinsam gehalten

Was die erfassten Halter dieses Wertpapiers am häufigsten sonst noch halten — Zählungen gemeinsamer Eigentümerschaft, keine fundamentalen Zusammenhänge.

Insider-Transaktionen

Käufe auf dem offenen Markt (P)

Keine Insider-Käufe auf dem offenen Markt in unserem Erfassungszeitraum.

Verkäufe auf dem offenen Markt (S)

Aug 17 Jonsson Patrik

Officer · 6.50K Ant. · $7.64M

Aug 10 Zakrowski Donald A

Officer · 2.00K Ant. · $2.37M

Aug 07 Hakim Anat

Officer · 5.00K Ant. · $5.95M

Zuteilungen, Ausübungen und Steuereinbehalte werden hier nie als Käufe oder Verkäufe gezählt. Methodik

Wirtschaftliches Eigentum
Jul 23 SC 13G/A — LILLY ENDOWMENT INC

Original-SEC-Einreichung anzeigen ↗

In den Nachrichten
Aug 24 FDA Clears Roche And Eli Lilly's Alzheimer's Blood Test ↗

The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify…

Forbes
Aug 24 FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly ↗

The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed…

WSJ
Aug 24 Roche, Eli Lilly's Alzheimer's blood test gets FDA clearance ↗

The U.S. Food and Drug Administration has cleared Roche and partner Eli Lilly's blood test to help ​identify signs of…

Reuters
Aug 24 Eli Lilly Launches Foundayo Weight-Loss Pill in U.K. ↗

The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event…

WSJ
Aug 23 Eli Lilly launches oral weight-loss pill Foundayo in UK ↗

Eli Lilly said on Monday it has launched its oral pill, ​Foundayo, in the UK for weight ‌management and type 2…

Reuters
Herkunft: Beteiligung aus geparsten 13F-Common-Stock-Positionen (verfolgte Grundgesamtheit, vergleichbare Sets für Veränderungen); Insider-Zeilen aus Formularen 3/4/5; Beteiligungen aus Schedules 13D/13G; jede Einreichung verlinkt auf das Original auf SEC EDGAR. Berichtszeitraum: Q2 2026 · Methodik · Über die API abrufen